ArticleCurrent drug delivery2026
Starch Biopolymer Functionalized with
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia. Natural compounds derived from plants, such as Ipomoea batatas, have shown therapeutic potential for its treatment.
methodsA starch-based biopolymer was developed and functionalized with a methanolic extract of
resultsThe biopolymer exhibited a swelling capacity of 333.03% and an encapsulation efficiency of 47.78%. In the zebrafish model, significant reductions in glucose, triglycerides, and cholesterol levels were observed, along with inhibition of advanced glycation end products (AGEs) formation in groups treated with IBM and BP-IBM. DISCUSSION: The results suggest that the biopolymer preserves the chemical integrity of the extract and improves its bioavailability, enabling a significant therapeutic effect. The dual administration routes provide flexibility and demonstrate the efficacy of the delivery system.
conclusionThe starch-based system functionalized with I. batatas extract proved to be a promising and non-toxic platform for the delivery of bioactive metabolites in type 2 diabetes models, with potential for future therapeutic applications.
Indexed as
Identifiers
40820451What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.